PHBI Pharmagreen Biotech Inc (PK)

(Check one):

☒     Form 10-K

☐     Form 20-F

☐     Form 11-K

☐     Form 10-Q

☐     Form 10-D

☐     Form N-SAR

☐     Form N-CSR

For Period Ended September 30, 2022                   

☐

Transition Report on Form 10-K

☐

Transition Report on Form 20-F

☐

Transition Report on Form 11-K

☐

Transition Report on Form 10-Q

☐

Transition Report on Form N-SAR

For the transition period ended ________________

PART I - REGISTRANT INFORMATION

Pharmagreen Biotech, Inc.

Full Name of Registrant

Former Name, if Applicable

2987 Blackbear Court

Address of Principal Executive Office (Street and Number)

Coquitlam, British Columbia V3E 3A2 Canada

City, State and Zip Code

☒

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Annual Report on Form 10-K cannot be filed without unreasonable effort or expense within the prescribed time period because management requires additional time to compile and verify the data required to be included in the report.

1.

Name and telephone number of person to contact in regard to this notification.

Peter Wojcik

(702)

803-9404

(Name)

(Area Code)

(Telephone Number)

2.

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).  ☒ Yes    ☐ No

3.

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes    ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

Pharmagreen Biotech, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

PHARMAGREEN BIOTECH, INC.

Date: December 28, 2022

By:

/s/ PETER WOJCIK

Peter Wojcik

Chief Executive Officer, President and Director.

3